Developer docs
API playgroundTry for free, no card

Search company profiles

Neurolief

Full company profile

uuid0000d3v

Namestring
Neurolief
Legal namestring
Neurolief Inc.
Websiteurl
neurolief.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Neurolief Inc. is a private medical technology company developing non-invasive brain neuromodulation therapies for neurological and psychiatric disorders, with its lead and only commercial product, ProlivRx, focused on major depressive disorder (MDD) in adults who have failed to achieve adequate improvement on at least one antidepressant medication. The company's core technology is external Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS), a focal, multi-channel neuromodulation method that delivers gentle electrical pulses through an external headset-style device to targeted occipital and trigeminal afferent neural pathways. ProlivRx was granted FDA Premarket Approval in December 2025 as the first and only prescription brain neuromodulation system authorized for at-home use in this indication, supported by clinical outcomes of 87% improvement in depression severity and 96% adherence across a structured 8-16 week treatment program with continuous physician oversight.

Neurolief generates revenue through prescription sales of the ProlivRx system, distributed exclusively via authorized prescribers, health systems, behavioral health programs, and (as of 2026) the Veterans Affairs Federal Supply Schedule. Its commercial model is enterprise field sales targeting psychiatrists, health systems, and VA VISNs, with multi-year contract pricing and a physician enrollment workflow rather than direct-to-consumer distribution. Reported cost-economics claims — $35,000 estimated annual cost avoidance per patient based on actuarial analysis of reduced escalation to in-clinic neuromodulation, ER visits, and inpatient utilization — are positioned for payer and health system buyers rather than as company revenue figures.

The company is strategically anchored by BrainsWay Ltd., which has invested a total of $11 million through a $5M August 2025 tranche and a $6M March 2026 milestone-based convertible loan, and which holds a call option to acquire all outstanding equity in Neurolief subject to performance milestones. Neurolief is led by CEO Scott F. Drees, with co-founder Amit Dar as CTO, and operates across Netanya, Israel and Coral Springs, Florida with 11-50 employees.

Short descriptiontext

Neurolief is a private medical technology company that developed ProlivRx, the first FDA-approved at-home brain neuromodulation system for adults with major depressive disorder who have failed antidepressant medication, selling it via authorized prescribers, health systems, and the Veterans Affairs healthcare network.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNetanya, Israel
HQ citystring
Netanya
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
brain neuromodulation devices, depression treatment systems, prescription neurostimulation therapy, at-home neuromodulation, mental health medical devices
Industry1 code
PRIMARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Offices of Physicians, Mental Health Specialists621112
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Neuromodulation Medical Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1ProlivRx System Sales
TypeHardware Sales
Description

Revenue generated from the sale of the FDA-approved ProlivRx neuromodulation system for at-home treatment of major depressive disorder, targeting health systems, VA healthcare facilities, and authorized prescribers.

prnewswire.co.uk
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Prescription therapy program
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing not publicly disclosed; therapy is prescription-only and delivered through authorized prescribers and health systems.

prolivrx.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Proliv®Rx
Description

FDA-approved at-home brain neuromodulation system for treatment-resistant Major Depressive Disorder. Provides focal external Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS) treatment.

prolivrx.com
Core offering1 text field

Neurolief develops and sells the ProlivRx (Proliv™Rx) system, an FDA-approved prescription brain neuromodulation device intended for adjunctive at-home treatment of Major Depressive Disorder in adults who have not achieved adequate improvement from at least one antidepressant medication. The device delivers focal external Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS) through gentle electrical pulses to targeted neural pathways and is operated under a structured 8–16 week physician-directed treatment program.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 87% of patients demonstrated improvement in depression severity after 16-week therapy program
+3 more records
Product overview1 text field

Neurolief offers a single unified product: the Proliv™Rx system. This is an FDA-approved, physician-directed, at-home brain neuromodulation therapy designed as an adjunctive treatment for adults with major depressive disorder who have failed to achieve satisfactory improvement from at least one previous antidepressant medication. The system combines an at-home treatment experience with continuous physician direction and visibility throughout the program, delivered as a structured 8-16 week treatment program.

Product and service1 record
1ProlivRx (Proliv™Rx) Brain Neuromodulation System
CategoryNeuromodulation Medical Devices
Description

FDA-approved prescription brain neuromodulation system intended as an adjunctive treatment for Major Depressive Disorder (MDD) in adults who failed to achieve satisfactory improvement from at least one previous antidepressant medication. Delivers focal, multi-channel external Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS) via gentle electrical pulses to targeted neural pathways, for use at home or in clinic under physician direction. Structured 8–16 week treatment program with continuous adherence and symptom tracking.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-21
Description

Strategic investment partnership established as Neurolief prepared for FDA approval and commercial launch of ProlivRx. BrainsWay's expertise and global reach with its Deep TMS system are expected to help scale product deployment. The partnership includes plans for further funding contingent on revenue targets and options for acquisition as Neurolief scales commercial operations in the U.S.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

BrainsWay develops Deep Transcranial Magnetic Stimulation (Deep TMS) systems for major depressive disorder and other psychiatric conditions. It is the most direct competitor in non-invasive brain neuromodulation for MDD and also holds an $11M strategic investment and call option to acquire Neurolief, making it both competitor and potential acquirer.

TypeDirect peer
Description

Neuronetics markets the NeuroStar TMS system, the most widely used transcranial magnetic stimulation therapy for treatment-resistant major depressive disorder in the US. It directly competes with Neurolief in the TRD neuromodulation segment, though NeuroStar requires clinic-based delivery while ProlivRx is at-home.

TypeDirect peer
Description

Flow Neuroscience offers a transcranial direct current stimulation (tDCS) headset for at-home treatment of depression, with regulatory approval in the EU and UK. It is a direct competitor in the at-home, prescription-style neuromodulation category for MDD that Neurolief occupies.

TypeDirect peer
Description

Sooma develops transcranial direct current stimulation (tDCS) devices for depression and other neurological conditions, with CE marking for home-use treatment of major depressive disorder. It competes in the same at-home neuromodulation segment for MDD as Neurolief's ProlivRx system.

5Magstim
TypeDirect peer
Description

Magstim manufactures transcranial magnetic stimulation systems widely used in clinical research and depression treatment. Its TMS platforms compete with Neurolief's neuromodulation approach in the TRD treatment pathway, though delivered in clinical settings rather than at home.

TypeDirect peer
Description

MagVenture develops and supplies transcranial magnetic stimulation systems used in depression treatment protocols across research and clinical settings. It competes in the broader non-invasive brain stimulation category for major depressive disorder that Neurolief addresses with ProlivRx.

7Neurosoft
TypeDirect peer
Description

Neurosoft manufactures repetitive transcranial magnetic stimulation (rTMS) systems for clinical use in psychiatric and neurological conditions, including depression. It operates in the same non-invasive brain stimulation treatment space for MDD as Neurolief.

8Apollo Neuroscience
TypeEmerging player
Description

Apollo Neuroscience develops wearable low-frequency stimulation devices designed for consumer and wellness use cases including stress, sleep, and focus. It is an emerging player in at-home neuromodulation with adjacent use cases to Neurolief's clinical MDD therapy, though positioned in the wellness category rather than prescription treatment.

TypeBroad incumbent
Description

Sage Therapeutics developed zuranolone (Zurzuvae), an FDA-approved oral therapy for postpartum depression and an investigated treatment for MDD, in partnership with Biogen. As a larger biopharmaceutical incumbent, it competes with Neurolief in the broader MDD treatment landscape, though through pharmacology rather than neuromodulation.

TypeEmerging player
Description

COMPASS Pathways is developing psilocybin therapy for treatment-resistant depression, with FDA Breakthrough Therapy designation. It is an emerging participant in the TRD treatment landscape and represents a potential alternative non-pharmacological intervention pathway alongside Neurolief's neuromodulation approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neurolief

Neuromodulation Medical Devicesneurolief.com

Neurolief is a private medical technology company that developed ProlivRx, the first FDA-approved at-home brain neuromodulation system for adults with major depressive disorder who have failed antidepressant medication, selling it via authorized prescribers, health systems, and the Veterans Affairs healthcare network.

What Neurolief does

Neurolief Inc. is a private medical technology company developing non-invasive brain neuromodulation therapies for neurological and psychiatric disorders, with its lead and only commercial product, ProlivRx, focused on major depressive disorder (MDD) in adults who have failed to achieve adequate improvement on at least one antidepressant medication. The company's core technology is external Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS), a focal, multi-channel neuromodulation method that delivers gentle electrical pulses through an external headset-style device to targeted occipital and trigeminal afferent neural pathways. ProlivRx was granted FDA Premarket Approval in December 2025 as the first and only prescription brain neuromodulation system authorized for at-home use in this indication, supported by clinical outcomes of 87% improvement in depression severity and 96% adherence across a structured 8-16 week treatment program with continuous physician oversight.

Neurolief generates revenue through prescription sales of the ProlivRx system, distributed exclusively via authorized prescribers, health systems, behavioral health programs, and (as of 2026) the Veterans Affairs Federal Supply Schedule. Its commercial model is enterprise field sales targeting psychiatrists, health systems, and VA VISNs, with multi-year contract pricing and a physician enrollment workflow rather than direct-to-consumer distribution. Reported cost-economics claims — $35,000 estimated annual cost avoidance per patient based on actuarial analysis of reduced escalation to in-clinic neuromodulation, ER visits, and inpatient utilization — are positioned for payer and health system buyers rather than as company revenue figures.

The company is strategically anchored by BrainsWay Ltd., which has invested a total of $11 million through a $5M August 2025 tranche and a $6M March 2026 milestone-based convertible loan, and which holds a call option to acquire all outstanding equity in Neurolief subject to performance milestones. Neurolief is led by CEO Scott F. Drees, with co-founder Amit Dar as CTO, and operates across Netanya, Israel and Coral Springs, Florida with 11-50 employees.

Neurolief firmographics

Firmographics
Name
Neurolief
Legal name
Neurolief Inc.
Website
https://neurolief.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Neurolief is a private medical technology company that developed ProlivRx, the first FDA-approved at-home brain neuromodulation system for adults with major depressive disorder who have failed antidepressant medication, selling it via authorized prescribers, health systems, and the Veterans Affairs healthcare network.
Ownership category
akta.pro rank

Neurolief industry classification

Industry
Product category
Neuromodulation Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Offices of Physicians, Mental Health Specialists (621112)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Brain neuromodulation devices
  • Depression treatment systems
  • Prescription neurostimulation therapy
  • At-home neuromodulation
  • Mental health medical devices

Where Neurolief is headquartered

Location

Headquarters

HQ city
Netanya
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

Neurolief business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. ProlivRx System Sales: Revenue generated from the sale of the FDA-approved ProlivRx neuromodulation system for at-home treatment of major depressive disorder, targeting health systems, VA healthcare facilities, and authorized prescribers.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractPrescription therapy program

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Neurolief product offering

Product offering

Core offering

Neurolief develops and sells the ProlivRx (Proliv™Rx) system, an FDA-approved prescription brain neuromodulation device intended for adjunctive at-home treatment of Major Depressive Disorder in adults who have not achieved adequate improvement from at least one antidepressant medication. The device delivers focal external Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS) through gentle electrical pulses to targeted neural pathways and is operated under a structured 8–16 week physician-directed treatment program.

Product overview

Neurolief offers a single unified product: the Proliv™Rx system. This is an FDA-approved, physician-directed, at-home brain neuromodulation therapy designed as an adjunctive treatment for adults with major depressive disorder who have failed to achieve satisfactory improvement from at least one previous antidepressant medication. The system combines an at-home treatment experience with continuous physician direction and visibility throughout the program, delivered as a structured 8-16 week treatment program.

Differentiator

Problem solved

Functional benefit

Brands

  • Proliv®Rx: FDA-approved at-home brain neuromodulation system for treatment-resistant Major Depressive Disorder. Provides focal external Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS) treatment.

Products and services

  • ProlivRx (Proliv™Rx) Brain Neuromodulation System FDA-approved prescription brain neuromodulation system intended as an adjunctive treatment for Major Depressive Disorder (MDD) in adults who failed to achieve satisfactory improvement from at least one previous antidepressant medication. Delivers focal, multi-channel external Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS) via gentle electrical pulses to targeted neural pathways, for use at home or in clinic under physician direction. Structured 8–16 week treatment program with continuous adherence and symptom tracking.

Quantifiable outcome

  • 87% of patients demonstrated improvement in depression severity after 16-week therapy program
  • +3 more outcomes

Companies that use Neurolief

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Neurolief technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Neurolief partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • BrainsWay Ltd.coreStrategic or Co-development Partner · 21 August 2025Strategic investment partnership established as Neurolief prepared for FDA approval and commercial launch of ProlivRx. BrainsWay's expertise and global reach with its Deep TMS system are expected to help scale product deployment. The partnership includes plans for further funding contingent on revenue targets and options for acquisition as Neurolief scales commercial operations in the U.S.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Neurolief competitors and assessment

Company assessment

Direct peers

  • BrainsWay: BrainsWay develops Deep Transcranial Magnetic Stimulation (Deep TMS) systems for major depressive disorder and other psychiatric conditions. It is the most direct competitor in non-invasive brain neuromodulation for MDD and also holds an $11M strategic investment and call option to acquire Neurolief, making it both competitor and potential acquirer.
  • Neuronetics: Neuronetics markets the NeuroStar TMS system, the most widely used transcranial magnetic stimulation therapy for treatment-resistant major depressive disorder in the US. It directly competes with Neurolief in the TRD neuromodulation segment, though NeuroStar requires clinic-based delivery while ProlivRx is at-home.
  • Flow Neuroscience: Flow Neuroscience offers a transcranial direct current stimulation (tDCS) headset for at-home treatment of depression, with regulatory approval in the EU and UK. It is a direct competitor in the at-home, prescription-style neuromodulation category for MDD that Neurolief occupies.
  • Sooma Medical: Sooma develops transcranial direct current stimulation (tDCS) devices for depression and other neurological conditions, with CE marking for home-use treatment of major depressive disorder. It competes in the same at-home neuromodulation segment for MDD as Neurolief's ProlivRx system.
  • Magstim: Magstim manufactures transcranial magnetic stimulation systems widely used in clinical research and depression treatment. Its TMS platforms compete with Neurolief's neuromodulation approach in the TRD treatment pathway, though delivered in clinical settings rather than at home.
  • MagVenture: MagVenture develops and supplies transcranial magnetic stimulation systems used in depression treatment protocols across research and clinical settings. It competes in the broader non-invasive brain stimulation category for major depressive disorder that Neurolief addresses with ProlivRx.
  • Neurosoft: Neurosoft manufactures repetitive transcranial magnetic stimulation (rTMS) systems for clinical use in psychiatric and neurological conditions, including depression. It operates in the same non-invasive brain stimulation treatment space for MDD as Neurolief.

Emerging players

  • Apollo Neuroscience: Apollo Neuroscience develops wearable low-frequency stimulation devices designed for consumer and wellness use cases including stress, sleep, and focus. It is an emerging player in at-home neuromodulation with adjacent use cases to Neurolief's clinical MDD therapy, though positioned in the wellness category rather than prescription treatment.
  • COMPASS Pathways: COMPASS Pathways is developing psilocybin therapy for treatment-resistant depression, with FDA Breakthrough Therapy designation. It is an emerging participant in the TRD treatment landscape and represents a potential alternative non-pharmacological intervention pathway alongside Neurolief's neuromodulation approach.

Broad incumbents

  • Sage Therapeutics: Sage Therapeutics developed zuranolone (Zurzuvae), an FDA-approved oral therapy for postpartum depression and an investigated treatment for MDD, in partnership with Biogen. As a larger biopharmaceutical incumbent, it competes with Neurolief in the broader MDD treatment landscape, though through pharmacology rather than neuromodulation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Neurolief social profiles

Digital presence

Neurolief compliance and trust

Trust signal

Compliance1 record

Neurolief financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neurolief leadership team

Management profile

Number of profiles

Profiles4 records

Neurolief funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neurolief M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neurolief

What does Neurolief do?

Neurolief develops and sells the ProlivRx (Proliv™Rx) system, an FDA-approved prescription brain neuromodulation device intended for adjunctive at-home treatment of Major Depressive Disorder in adults who have not achieved adequate improvement from at least one antidepressant medication. The device delivers focal external Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS) through gentle electrical pulses to targeted neural pathways and is operated under a structured 8–16 week physician-directed treatment program.

Is Neurolief a public or private company?

Neurolief is a private company. It is classified as venture growth investor backed and is currently operating.

When was Neurolief founded?

Neurolief was founded in 2014. It employs 11 to 50 people.

Where is Neurolief based?

Neurolief is headquartered in Netanya, Israel, in the Middle East region.

How does Neurolief make money?

One revenue line is on record: prolivRx System Sales.

Who are Neurolief's main competitors?

Direct peers on record are BrainsWay, Neuronetics, Flow Neuroscience, Sooma Medical, Magstim, MagVenture and Neurosoft. Emerging players are Apollo Neuroscience and COMPASS Pathways. Sage Therapeutics is listed as a broad incumbent.

Does Neurolief have an API?

No public API is recorded for Neurolief.

What industry is Neurolief in?

Neurolief's product category is Neuromodulation Medical Devices. Its primary akta.pro industry code is HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireNeurolief Secures Single Case Agreements with U.S. Payers for Proliv®Rx At-Home Depression TherapyNeurolief secured single case agreements with U.S. payers for its FDA-approved at-home depression therapy Proliv Rx. The MOOD study showed remission rates of 21.3% vs 6.0% at eight weeks and 31.7% at 16 weeks. The company is pursuing broader market access across payers, health systems, and the VA.PR NewswireNeurolief Expands Veterans' Access to Prescription Neuromodulation for Depression and Migraine Through New VA ContractNeurolief has secured a new contract with the U.S. Department of Veterans Affairs to prescribe its Proliv®Rx and Relivion®MG neuromodulation therapies at VA medical centers. This agreement expands access to these FDA-approved, non-invasive treatments for major depressive disorder and migraine among veterans, allowing patients to use the devices at home under physician supervision.PR NewswireNeurolief Expands Veterans' Access to Prescription Neuromodulation for Depression and Migraine Through New VA ContractNeurolief's Proliv Rx and Relivion MG are now prescribed at multiple VA medical centers for veterans with treatment-resistant depression and migraine. Proliv Rx, FDA-approved in December 2025, showed 21.3% remission versus 6.0% in sham; Relivion MG cleared 46% pain-free versus 11.8% in sham. The company aims to expand access to these neuromodulation therapies.BioSpaceNeurolief to Showcase Proliv®Rx at APA 2026, Highlighting FDA-Approved, Physician-Directed At-Home Brain Stimulation for Major Depressive DisorderNeurolief will showcase its FDA-approved Proliv Rx brain stimulation therapy at the APA Annual Meeting in May 2026. The therapy, for adults with major depressive disorder unresponsive to antidepressants, is delivered at home under physician supervision. The MOOD study showed 31.7% remission and 70.7% clinically substantial improvement at 16 weeks.PR NewswireNeurolief to Showcase Proliv®Rx at APA 2026, Highlighting FDA-Approved, Physician-Directed At-Home Brain Stimulation for Major Depressive DisorderNeurolief will showcase its FDA-approved Proliv Rx brain stimulation therapy for major depressive disorder at the APA Annual Meeting in San Francisco. The therapy, based on eCOT-AS, is physician-supervised and can be delivered at home or in clinic. The MOOD study showed 31.7% remission and 70.7% clinically substantial improvement at 16 weeks.Pulse 2.0Neurolief: $6 Million Investment Raised For FDA-Approved At-Home Depression Neuromodulation TherapyNeurolief has secured a $6 million milestone-based investment from BrainsWay following FDA Premarket Approval of its ProlivRx system, an at-home brain neuromodulation therapy for adults with major depressive disorder. ProlivRx, which received FDA approval in December 2025, is positioned as the first prescription neuromodulation system for depression that can be self-administered at home under physician supervision. The partnership underscores increasing industry momentum behind non-invasive neurostimulation technologies, with Neurolief planning to use the funding to expand commercial adoption and scale its delivery model.FinSMEsNeurolief Raises Additional $6M InvestmentNeurolief, a Coral Springs, Florida-based medical technology company, secured a $6 million investment from BrainsWay Ltd., following the FDA Premarket Approval of its Proliv™Rx brain neuromodulation system for adults with major depressive disorder. The company plans to use the proceeds to expand its operations and R&D efforts. This funding comes after the company received regulatory approval for its prescription therapy, which patients self-administer at home under physician supervision.PR NewswireNeurolief Secures Additional $6 Million Investment Following FDA Approval of Proliv™Rx, Expanding Access to Brain Neuromodulation Therapy for Patients with Inadequate Response to AntidepressantsNeurolief announced a $6 million milestone-based investment from BrainsWay Ltd. following FDA Premarket Approval of its Proliv™Rx brain neuromodulation system in December 2025. Proliv™Rx is the first and only FDA-approved prescription brain neuromodulation system for at-home self-administration by adults with major depressive disorder who have not adequately responded to antidepressant medication. The investment is intended to accelerate U.S. commercialization and expand access to next-step depression care outside of specialized treatment facilities.PR NewswireNeurolief Secures Additional $6 Million Investment Following FDA Approval of Proliv™Rx, Expanding Access to Brain Neuromodulation Therapy for Patients with Inadequate Response to AntidepressantsNeurolief, a medical technology company developing neuromodulation therapies for mental health conditions, secured a $6 million milestone-based investment from BrainsWay Ltd. following FDA Premarket Approval of its Proliv™Rx brain neuromodulation system in December 2025. Proliv™Rx is the first and only FDA-approved prescription brain neuromodulation system for adults with major depressive disorder who have not achieved adequate response to at least one antidepressant medication. The investment will accelerate the U.S. rollout of the at-home therapy, which addresses treatment gaps for depression patients unable to access specialized treatment centers.Refresh MiamiNeurolief raises $6M to fuel U.S. rollout of at-home depression therapyNeurolief, a Coral Springs-based medical technology company, has secured a $6 million milestone-based investment from Israeli medtech company BrainsWay Ltd to accelerate the U.S. rollout of Proliv Rx, its FDA-approved at-home brain neuromodulation system for treatment-resistant Major Depressive Disorder. Proliv Rx, which received FDA premarket approval, is positioned as the first and only FDA-approved, at-home prescription therapy for adults with MDD who have failed at least one medication trial. According to a 2025 eMerge Insights report, South Florida medtech companies raised $821 million across 56 deals in 2024, with over $600 million already logged in Q1 2025.